Genzyme Corporation FDA Inspection Record
Genzyme Corporation is an FDA-inspected facility (FEI 1221955) located in Cambridge, MA, US. RegDataLab tracks 9 FDA inspections at this facility.
What FDA found at this site
- Latest inspection
- Aug 10, 2016: No Action Indicated (NAI)
- Inspections on record
- 9 (4 VAI, 5 NAI)
- Last OAI inspection
- None on record
- Warning letters
- None matched to this FEI. Many letters do not state an FEI: search warning letters by company name
- Recalls as the recalling firm
- 4, latest Feb 16, 2016
- Import refusals
- 1
Inspections and what FDA cited
| Date | Result | What FDA cited |
|---|---|---|
| Aug 10, 2016 | No Action Indicated (NAI) | No citations listed |
| Aug 22, 2014 | No Action Indicated (NAI) | No citations listed |
| Mar 25, 2014 | No Action Indicated (NAI) | No citations listed |
| Sep 30, 2013 | Voluntary Action Indicated (VAI) | No citations listed |
| Oct 5, 2012 | No Action Indicated (NAI) | No citations listed |
| Jun 28, 2011 | Voluntary Action Indicated (VAI) | Test methods (21 CFR 211.165(e)) Investigations of discrepancies, failures (21 CFR 211.192) |
| Jun 2, 2010 | Voluntary Action Indicated (VAI) | Late submission of 15-day report (21 CFR 314.80(c)(1)(i)) Submission of report follow-up (21 CFR 314.80(c)(1)(ii)) Failure by applicant to report ADE (21 CFR 314.80(c)) Late submission of annual safety reports (21 CFR 314.80(c)(2)) and 1 more |
| Sep 9, 2009 | No Action Indicated (NAI) | No citations listed |
| Oct 20, 2008 | Voluntary Action Indicated (VAI) | Investigator non-compliance (21 CFR 312.56(b)) General responsibilities of sponsors (21 CFR 312.50) |
Recalls
| Date | Class | Recall | Product and reason |
|---|---|---|---|
| Feb 16, 2016 | Class II | D-0729-2016 | Thyrogen (thyrotropin alfa for injection), 0.9 mg/mL after reconstitution, For… and 1 more product Presence of Particulate Matter: Glass particles found in the product after reconstitution. |
| Dec 8, 2015 | Class III | D-0799-2016 | Lumizyme (alglucosidase alpha), 50 mg/vial, For Intravenous Infusion Only, Rx Only… Labeling: Incorrect or Missing Lot and/or Exp Date |
| Mar 24, 2014 | Class III | B-0992-14 | Genzyme Thymoglobulin¿ [Anti-thymocyte Globulin (Rabbit)], 25 mg (NDC 58468-0080-01) Anti-Thymocyte Globulin (Rabbit) 25 mg, with a trend approaching the upper limit on the molecular size distribution tests for polymers… |
| Jan 31, 2012 | Class II | D-1203-2012 | FLUDARA (fludarabine phosphate) for injection, 50 mg, Single Dose Vial, For Intravenous… Lack of assurance of sterility: Based on joint FDA/EMA inspection conducted at the manufacturer Ben Venue Laboratories in Bedford, Ohio, in… |
FDA record score
0 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.
6 records behind this number
| Record | Date | Points x age weight | Adds |
|---|---|---|---|
| Class II recall D-0729-2016, this FEI as the recalling firm | Feb 16, 2016 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Sep 30, 2013 | 10 years or older, so it adds no points | 0 |
| Class II recall D-1203-2012, this FEI as the recalling firm | Jan 31, 2012 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Jun 28, 2011 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Jun 2, 2010 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Oct 20, 2008 | 10 years or older, so it adds no points | 0 |
When each source was last refreshed
| Records | Last refreshed | Source as of | Status |
|---|---|---|---|
| Inspections | Nov 22, 2026 | Newest record Nov 9, 2026 | Current |
| Inspection citations | Nov 22, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions (warning letters, injunctions and other action types) | Nov 22, 2026 | Newest record Nov 13, 2026 | Current |
| Warning letter text | Nov 22, 2026 | Newest record Nov 17, 2026 | Current |
| Recalls (Enforcement Report) | Nov 22, 2026 | Newest record Nov 18, 2026 | Current |
| Form 483s and inspection documents | Nov 18, 2026 | Newest record Nov 17, 2026 | Current |
| Import refusals | Nov 22, 2026 | Newest record Nov 12, 2026 | Current |
Reviewing Genzyme Corporation as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Genzyme Corporation yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Facility details
- Company
- Genzyme Corporation
- Location
- Cambridge, MA (US)
- Source
- inspections